Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

Journal of the American Academy of Dermatology

Volumn 52, Issue 3 Pt 1, 2005, Pages 425-433

  Leonardi, Craig L ^a   Papp, Kim A ^a   Gordon, Kenneth B ^a   Menter, Alan ^a   Feldman, Steven R ^a   Caro, Ivor ^a   Walicke, Patricia A ^a   Compton, Peter G ^a   Gottlieb, Alice B ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11 ANTIGEN; DERMATOLOGICAL AGENT; EFALIZUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PSORIASIS;

MLCS; MLOWN;

EID: 17144388751     PISSN: None     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2004.09.029     Document Type: Article

References (0)